Systemic Sclerosis Drug
Systemic sclerosis is an intractable disease in which collagen accumulates in the skin and organs, causing fibrosis. There is no cure other than symptomatic treatment to relieve symptoms.
We found a compound that suppresses the accumulation of collagen HPH-15. This compound healed thickened skin in Systemic Sclerosis model mice.
We have now completed non-clinical studies of HPH-15 and currently we are in preparation for Phase I trials.
In recent years, various anti-AIDS drugs have been developed, and it has become possible to control HIV infection so that it does not develop. However, since HIV has not been eliminated from the infected person's body, AIDS will develop if the drug is stopped.
We have developed a drug, L-HIPPO, that traps HIV inside HIV-infected cells and kills the infected cells as well. We are conducting research aimed at a complete cure for AIDS.
Cerebral infarction is a blockade of brain arteries resulting in ischemia and cerebral cell death. This process is suppressed by neuroprotectants.
We developed a new compound CNN that scavenges toxic substance HNE produced by cerebral ischemia. CNN showed effect in Mongolian Gerbil ischemia model, as demonstrated by a collaboration with department of neurosurgery, Kurume University.
Phytic acid has a variety of activities, such as suppressing cancer cell proliferation, improving diabetes, enhancing immunity, suppressing kidney stone formation, lowering cholesterol, and reducing the risk of developing coronary artery disease. However, phytic acid does not easily pass through cell membranes, limiting the ability to study its intracellular functions and link it to drugs.
We have created a phytic acid prodrug that permeates the cell membrane and releases phytic acid intracellularly. This compound was named Pro-IP6. We aim to develop it as an antidiabetic drug and as a reagent for life science research.